In vivo concentration of tofacitinib might be above the inhibition levels of JAK1 and JAK3, but not that of JAK2, which facilitated the expansion of MDSCs in the lung of ILD-induced SKG mice. This evidence concerns the gene JAK2 and interstitial lung disease.